Latest Breaking News On - Iterum therapeutics plc - Page 1 : comparemela.com

Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call Transcript

Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Corey fishmanEd arceMichael okunewitchLouise barrettCoreyn fishmanThomas yipJudy matthewsJudithm matthewsJason mccarthyDivision of antiLegal affairsIterum therapeutics plcMaxim groupIterum therapeuticsCall transcript mayIterum therapeutics first quarter

Iterum Therapeutics Plc (ITRM) Announces Resignation of Mark Chin from Board

Iterum Therapeutics Plc (ITRM) Announces Resignation of Mark Chin from Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mark chinCompany board of directorsBoard of directors iterum therapeutics plcIterum therapeutics plc

Iterum Therapeutics Plc s (ITRM) Stock: A 61 03% Annual Performance Rate

Iterum Therapeutics Plc s (ITRM) Stock: A 61 03% Annual Performance Rate
newsheater.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsheater.com Daily Mail and Mail on Sunday newspapers.

United statesGrand viewPuttagunta sailajaIterum therapeutics plcView researchGrand view researchIterum therapeuticsDay moving

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript

Operator: Hello, everyone, and welcome to the Iterum Therapeutics Third Quarter 2023 Financial Results and Business Update. My name is Harry, and I’ll be your operator today.

Ed arceLouise barrettJudy matthewsCorey fishmanJudith matthewsIterum therapeutics plcLegal affairsIterum therapeuticsCall transcript novemberIterum therapeutics third quarterSenior vice presidentInterim therapeutic third quarterBusiness update conferenceRisk factorsHighest ratesComplete response letter

Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 26 5% in April

Iterum Therapeutics plc (NASDAQ:ITRM – Get Rating) saw a large decline in short interest in April. As of April 30th, there was short interest totalling 76,400 shares, a decline of 26.5% from the April 15th total of 103,900 shares. Based on an average daily volume of 63,500 shares, the short-interest ratio is presently 1.2 days. […]

Coreyn fishmanGoldman sachs group incIterum therapeutics plcDimensional fund advisorsRenaissance technologiesIterum therapeuticsGet ratingSachs groupTherapeutics plcIterum therapeutics dailyNasdaq itrm